Imaging damaged lung tissue using compositions
The present invention relates to methods and compositions for targeting damaged lung tissue. Compositions provided feature a targeting moiety coupled to one or more other moieties, including, for example, a cross-linkable moiety, an imaging moiety, and/or one or more other targeting moieties. The methods and compositions of the invention find use, for example, in detecting and treating a pulmonary condition such as emphysema.
1 . A composition comprising an imaging moiety and a targeting moiety wherein said moieties are coupled and wherein said targeting moiety targets damaged lung tissue.
2 . The composition as recited in claim 1 wherein said lung tissue comprises epithelial lining fluid.
3 . The composition as recited in claim 1 wherein said composition does not comprise a polysaccharide or a carbohydrate moiety.
4 . The composition as recited in claim 1 wherein said composition does not comprise an antibody.
5 . The composition as recited in claim 1 wherein said composition does not comprise a mutant plasminogen activator-inhibitor type 1 .
6 . The composition as recited in claim 1 wherein said composition does not comprise a lung membrane dipeptidase-binding molecule.
7 . The composition as recited in claim 1 wherein said targeting moiety does not target a lung membrane dipeptidase.
8 . The composition as recited in claim 1 wherein said targeting moiety targets a damage-correlated moiety.
9 . The composition as recited in claim 8 wherein said damage-correlated moiety comprises a cell surface marker.
10 . The composition as recited in claim 8 wherein said damage-correlated moiety comprises an ECM component.
11 . The composition as recited in claim 1 wherein said targeting moiety targets elastase.
12 . The composition as recited in claim 1 wherein said targeting moiety targets neutrophil elastase.
13 . The composition as recited in claim 1 wherein said targeting moiety comprises a protease inhibitor moiety.
14 . The composition as recited in claim 1 wherein said targeting moiety comprises an alpha-1 antitrypsin moiety.
15 . The composition as recited in claim 14 wherein said alpha-1 antitrypsin moiety is a recombinant alpha-1 antitrypsin moiety.
16 . The composition as recited in claim 1 wherein said targeting moiety comprises an elafin moiety.
17 . The composition as recited in claim 16 wherein said elafin moiety is a recombinant elafin moiety
18 . The composition as recited in claim 1 wherein said targeting moiety comprises a serpin moiety.
19 . The composition as recited in claim 18 wherein said serpin moiety is a recombinant serpin moiety
20 . The composition as recited in claim 18 wherein said serpin moiety is a secretory leukoprotease inhibitor (SLP1) moiety.
21 . The composition as recited in claim 20 wherein said secretory leukoprotease inhibitor (SLP1) moiety is a recombinant secretory leukoprotease inhibitor (SLP1) moiety.
22 . The composition as recited in claim 1 wherein said targeting moiety targets at least one matrix metalloproteinase selected from MMP-1, MMP-2, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, and MMP-9.
23 . The composition as recited in claim 22 wherein said composition does not comprise a hyaluronic acid or a salt thereof.
24 . The composition as recited in claim 1 wherein said targeting moiety targets desmosine and/or isodesmosine.
25 . The composition as recited in claim 1 wherein said targeting moiety targets CD8 and/or CD4.
26 . The composition as recited in claim 1 wherein said targeting moiety targets a smoke-related moiety.
27 . The composition as recited in claim 1 wherein said imaging moiety comprises a contrasting agent.
28 . The composition as recited in claim 27 wherein said contrasting agent is non-ionic.
29 . The composition as recited in claim 27 wherein said contrasting agent is ionic
30 . The composition as recited in claim 1 wherein said imaging moiety comprises at least one metal compound selected from a tantalum compound and a barium compound.
31 . The composition as recited in claim 1 wherein said imaging moiety comprises iodine.
32 . The composition as recited in claim 1 wherein said imaging moiety comprises at least one organic iodo acid selected from an iodo carboxylic acid, a triiodophenol, an iodoform, and a tetraiodoethylene.
33 . The composition as recited in claim 1 wherein said imaging moiety comprises a non-radioactive moiety
34 . The composition as recited in claim 1 wherein said imaging moiety comprises a proton-emitting moiety.
35 . The composition as recited in claim 1 wherein said imaging moiety comprises a radiopaque moiety and/or a radioactive moiety.
36 . The composition as recited in claim 1 wherein said imaging moiety comprises a magnetic moiety.
37 . The composition as recited in claim 1 wherein said imaging moiety comprises a radiopharmaceutical.
38 . The composition as recited in claim 1 wherein said imaging moiety comprises an In-111 moiety.
39 . The composition as recited in claim 1 wherein said imaging moiety comprises a Tc-99m moiety.
40 . The composition as recited in claim 1 wherein said imaging moiety comprises an Xe-133 moiety.
41 . The composition as recited in claim 1 wherein said composition is less than 10 microns.
42 . The composition as recited in claim 1 wherein said composition is less than 5 microns.
43 . The composition as recited in claim 1 wherein said composition is less than 1 micron.
44 . The composition as recited in claim 1 wherein said composition further comprises a coupled cross-linkable moiety and/or another coupled targeting moiety.